Abacavir (cas 136470-78-5)☆

Add time:09/07/2019    Source:sciencedirect.com

Abacavir (ABC) is a nucleoside HIV-1 reverse transcriptase inhibitor, approved for clinical use in 1998. It is part of the recommended first-line therapy for treating HIV-1 infected children and adolescents. Resistance is determined by the M184V mutation, but additional substitutions are needed to achieve high-level resilience. Toxicity is mainly due to a hypersensitivity reaction syndrome, which is genetically linked to the HLA-B*5701 allele. ABC can be considered a valuable alternative for second-line regimens in experienced adult patients and it is also being considered as first-line therapy in drug naïve HIV-1 infected adults, in combination with dolutegravir and lamivudine.

We also recommend Trading Suppliers and Manufacturers of Abacavir (cas 136470-78-5). Pls Click Website Link as below: cas 136470-78-5 suppliers

Prev:Original articleSwitching from Abacavir (cas 136470-78-5)/lamivudine plus nevirapine to Abacavir (cas 136470-78-5)/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)Abacavir (cas 136470-78-5)/lamivudine/dolutégravir après Abacavir (cas 136470-78-5)/lamivudine plus névirapine chez des adultes infectés par le VIH et contrôlés virologiquement (étude SWAD)
Next:Abacavir (cas 136470-78-5) and cardiovascular disease: A critical look at the data)